The Study of Efficacy and Safety of SebclairÂ® in Mild to Moderate Degree Seborrheic Dermatitis (SD)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20170206007

Enrollment

Registered

2017-02-06

Start date

2017-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild to moderated seborrheic dermatitis seborrheic dermatitis sebclair

Interventions

cream applies twice daily,cream applied twice daily

Experimental Device,Placebo Comparator Device

sebclair,cold cream

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 18-60 years with mild to moderate seborrheic dermatitis

Exclusion criteria

Exclusion criteria: those with underlying medical problems or with current medications taken. those who stop using topical medications not less than two weeks or systemic medications not less then 4 weeks Pregnancy or lactating status

Design outcomes

Primary

Measure	Time frame
total number of day of steroid used 6 months mean	—

Secondary

Measure	Time frame
side effect of sebclair 6 months frequency or percent,the time to achieve clear or almost clear of seborrheic dermatitis 1 months mean	—

Countries

Thailand

Contacts

Public Contactchanat kumtornrut

chulalongkorn university

chanat_1@yahoo.com0814594965

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026